Furthermore, a recent study aimed at illustrating the effect of CKI on tumor immunity demonstrates that CKI relieves the immunosuppression mediated by tumor-associated macrophages and afterwards alleviates the immunosuppressive effects on CD8+ T cells, which enhances the efficacy of low-dose sorafenib and avoids chemotherapy-induced adverse effects (10). The gene discussed is CD8A; the disease is neoplasm.